首页> 外文OA文献 >Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus
【2h】

Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus

机译:B和T淋巴细胞减毒剂(BTLA)的单克隆抗体对体外B细胞增殖没有影响,并且以相对于激活刺激的顺式而非反式形式存在时,具有抑制体外T细胞增殖的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

B and T lymphocyte attenuator (BTLA) is an immunoglobulin superfamily member surface protein expressed on B and T cells. Its ligand, herpesvirus entry mediator (HVEM), is believed to act as a monomeric agonist that signals via the CRD1 of HVEM to inhibit lymphocyte activation: HVEM is also the receptor for lymphotoxin-α and LIGHT, which both bind in the CRD2 and CRD3 domains of the HVEM molecule, and for CD160 which competes with BTLA. We have shown that recombinant HVEM and a panel of different monoclonal antibodies specifically bind murine BTLA on both B and T cells and that some antibodies inhibit anti-CD3ε-induced T cell proliferation in vitro, but only when constrained appropriately with a putatively cross-linking reagent. The antibodies had no significant effect on in vitro T cell proliferation in a mixed lymphocyte reaction (MLR) assay nor on in vitro DO11.10 antigen-induced T cell proliferation. None of these antibodies, nor HVEM-Fc, had any significant effect on in vitro B cell proliferation induced by anti-immunoglobulin M antibodies (±anti-CD40) or lipopolysaccharide. We further elucidated the requirements for inhibition of in vitro T cell proliferation using a beads-based system to demonstrate that the antibodies that inhibited T cell proliferation in vitro were required to be presented to the T cell in a cis, and not trans, format relative to the anti-CD3ε stimulus. We also found that antibodies that inhibited T cell proliferation in vitro had no significant effect on the antibody captured interleukin-2 associated with the in vivo activation of DO11.10 T cells transferred to syngeneic recipient BALB/c mice. These data suggest that there may be specific structural requirements for the BTLA molecule to exert its effect on lymphocyte activation and proliferation.
机译:B和T淋巴细胞减毒剂(BTLA)是在B和T细胞上表达的免疫球蛋白超家族成员表面蛋白。据信其配体疱疹病毒进入介体(HVEM)可作为单体激动剂,通过HVEM的CRD1发出信号以抑制淋巴细胞活化:HVEM还是淋巴毒素α和LIGHT的受体,两者都结合在CRD2和CRD3中HVEM分子的结构域,以及与BTLA竞争的CD160。我们已经显示重组HVEM和一组不同的单克隆抗体特异性结合B和T细胞上的鼠BTLA,并且某些抗体在体外抑制抗CD3ε诱导的T细胞增殖,但仅在适当地限制了假定的交联的情况下试剂。在混合淋巴细胞反应(MLR)分析中,该抗体对体外T细胞增殖无明显影响,对体外DO11.10抗原诱导的T细胞增殖无明显影响。这些抗体和HVEM-Fc均对抗免疫球蛋白M抗体(±抗CD40)或脂多糖诱导的体外B细胞增殖没有任何显着影响。我们进一步阐明了使用基于珠的系统抑制体外T细胞增殖的要求,以证明需要在体外​​抑制T细胞增殖的抗体必须以顺式而非反式形式相对于T细胞呈递。抗CD3ε刺激。我们还发现,在体外抑制T细胞增殖的抗体对与转移至同种受体BALB / c小鼠的DO11.10 T细胞的体内活化相关的捕获的白细胞介素2抗体没有显着影响。这些数据表明,对BTLA分子可能具有特定的结构要求,以发挥其对淋巴细胞活化和增殖的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号